TP53 and neuroblastoma: The SK-N-BE(2)-C cell line was chosen for screening because it exhibits an intermediate response to HDAC8 inhibitor treatment and is one of the most aggressive neuroblastoma cell lines derived from a relapsed MYCN-amplified tumor with a TP53 mutation [12].